Investigational Drug Information for Entinostat
✉ Email this page to a colleague
What is the drug development status for Entinostat?
Entinostat is an investigational drug.
There have been 70 clinical trials for Entinostat.
The most recent clinical trial was a Phase 2 trial, which was initiated on March 29th 2014.
The most common disease conditions in clinical trials are Breast Neoplasms, Carcinoma, and Lung Neoplasms. The leading clinical trial sponsors are National Cancer Institute (NCI), Syndax Pharmaceuticals, and Merck Sharp & Dohme Corp.
Summary for Entinostat
US Patents | 0 |
International Patents | 0 |
US Patent Applications | 1,766 |
WIPO Patent Applications | 1,146 |
Japanese Patent Applications | 447 |
Clinical Trial Progress | Phase 2 (2014-03-29) |
Vendors | 120 |
Recent Clinical Trials for Entinostat
Title | Sponsor | Phase |
---|---|---|
Phase I/II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG With Entinostat and Nivolumab as Adjuvant Therapy Following Chemoradiation Therapy With or Without Surgery for Locally Advanced Esophageal Cancer | National Cancer Institute (NCI) | Phase 1/Phase 2 |
Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors and Lymphomas | National Cancer Institute (NCI) | Phase 1/Phase 2 |
Phase I/II Trial of the Combination of Bintrafusp Alfa (M7824), Entinostat and NHS-IL12 (M9241) in Patients With Advanced Cancer | National Cancer Institute (NCI) | Phase 1/Phase 2 |
Clinical Trial Summary for Entinostat
Top disease conditions for Entinostat
Top clinical trial sponsors for Entinostat
US Patents for Entinostat
Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
---|---|---|---|---|
>Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |